Long-acting lyophilized powder injection preparation of cisatracurium besilate

Abstract

The invention relates to a long-acting lyophilized powder injection preparation of cisatracurium besilate. The long-acting lyophilized powder injection preparation of the cisatracurium besilate is prepared from the following components in parts by weight: 3-10 parts of cisatracurium besilate, 10-40 parts of polyethylene glycol-phosphatidyl ethanolamine, 10-30 parts of soya bean lecithin, 5-15 parts of sodium deoxycholate, 0.15-0.50 part of an antioxidant, 0.5-1 part of polyvinylpyrrolidone and 5-25 parts of a frozen-dried supporting agent. The preparation can be used for intravenous administration, the problem of the mass stability is effectively solved, the pharmacodynamic action time and the bioavailability of the preparation are improved, and meanwhile, the toxic or side effect is also relatively reduced.

Description

technical field

[0001] The invention belongs to the field of chemical pharmacy, and in particular relates to a cisatracurium besylate composition for injection and a preparation method thereof, in particular to a long-acting freeze-dried powder injection of cisatracurium besylate and a preparation method thereof . Background technique

[0002] Cisatracurium besilate (cisatracurium besilate) is a new type of benzylisoquinoline intermediate-effect non-depolarizing muscle relaxant, one of the ten isomers of atracurium, and the latest generation of muscle relaxant , has similar muscle relaxant effect and metabolic process as atracurium besylate. Cisatracurium besylate has the characteristics of metabolism through non-hepatic and non-kidney pathways and cardiovascular stability. The muscle relaxation effect is 3 times stronger than that of atracurium, and does not release histamine, and the cardiovascular reaction is small. It is more ideal A medium-acting non-depolarizing musc...

Images